Grp78 and Grp94, were indeed discovered in glucose starvation
experiments between the mid-seventies and eighties by Pastan's lab [3] . Gething and Sambrook understood the importance of chaperone up-regulation and discovered common elements in their promoters that govern chaperones' transcriptional control.
It was in 1992 when the term "Unfolded Protein Response" (UPR) was first used [4] .
The yeast IRE1 trans-membrane kinase and ribonuclease was the first sensor of the accumulation of unfolded proteins in ER cloned in 1998 by two labs, Sambrook and Walter [5, 6] . Beautifully surprising and somehow expected is the story of mammalian UPR sensors' identification [7] [8] [9] [10] [11] . As compared to that of the yeast, the mammalian system shows much more complexity and redundancy due to contributions from at least 3 major pathways of UPR: IRE1α and IREα, PERK and ATF6.
PERK added extra release to the stressed ER by translational attenuation of new protein synthesis. Before XBP1 was identified and connected to UPR, it was thought that ATF6 fulfilled Hac1 function in higher eukaryotes [12, 13] . as part of a sophisticated proteostatic cellular network. This system appears to be increasingly complicated, yet maintains uniqueness and elegance in its unusual regulation and broad importance to the cell [15] .
Connections to cancer development have also become increasingly evident. It has been well established that cancer cells experience multiple occurrences of ERSR [16] . Cancer cells deficient in UPR genes do not grow well or form metastases and have abnormal vascularization [17] . The dream of each oncologist is to have therapeutics that will render such properties to tumors, and our main challenge is to supply these therapies. Hopefully, it can be done through the cunning design of new therapeutics specific to UPR pathways that will inhibit cytoprotective and dormancy programs configured by ERSR and augment the non -protective apoptotic arm of ERSR [16, 18] . This can be accomplished with an in-depth The ERSC journal is peer-reviewed and an Open Access, there are also no page charges till 2014. We envision the solidification of work in a dedicated journal that will contribute tremendously to our understanding of the role that ERSR has in cancer pathophysiology, as well as promote communication and the exchange of ideas in the international research community laboring in this endeavor. We hope the journal Endoplasmic Reticulum Stress in Cancers will contribute to the proactive advancement of this field, to its direct effects on cancer treatment and prevention. We look forward to incorporating your work into
Endoplasmic Reticulum Stress in Cancers.
survival of cancer cells during episodes of hypoxia and nutrient deprivation experienced by every "successful tumor," and their up-regulation has cytoprotective effects against conventional agents of chemotherapy [19] [20] [21] . The expression of ER-resident proteins on the cell surface due to a breach in ER quality control during episodes of UPR has been found to be very "beneficial"
for many tumors and directly correlates with a poor prognosis.
While BiP has been shown to act as a prosurvival receptor, PDI has proven to contribute to antigen shedding on tumors thus further aiding in their evasion of the immune system [22] .
Moreover, tumor dormancy has confirmed its dependence upon UPR signaling through interaction with kinase cascades (p38 and ERK) regulating growth [23, 24] . Tumor associated-inflammation and supportive micro-environments are partly a product of UPR associated signaling [25] [26] [27] . Induction of UPR through inhibition of proteasomal degradation and UPR-associated apoptotic signaling is thought to be beneficial in treating many tumors when in combination with conventional agents of chemotherapy [28, 29] . Numerous clinical trials are currently being performed to validate this approach and to ensure the use of ERS inducers in cancer patients [30, 31] .
This field is exploding with new knowledge [32] . By 1999, the number of manuscripts published on UPR was in the range 
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